# US 2025/0049750 A1 · Maltodextrin formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049750 A1
- Document ID: US20250049750A1
- Status: Published application
- Kind: A1
- Application number: 18/799,545
- Filed: 2024-08-09
- Published: 2025-02-13
- Earliest claimed: 2023-08-09
- Assignees: Amazentis SA
- Applicants: Amazentis SA
- Inventors: Christopher L. Rinsch; Anurag Singh
- Web page: https://patentgrep.com/patent/US20250049750A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/37: Coumarins, e.g. psoralen
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/718: Starch or degraded starch, e.g. amylose, amylopectin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

Disclosed are aqueous formulations comprising urolithins particularly water-based formulations comprising urolithins and maltodextrin. Also disclosed are compositions for admixture with water, methods for the preparation of such aqueous formulations, and to the uses of such formulations for both the treatment of diseases, disorders and conditions, for example, diseases disorders or conditions characterized by inadequate mitochondrial function and for administration to generally healthy individuals for example, for improving health and improving muscle function and performance.

## Claims

### Claim 1

A composition, for admixture with water, comprising:
(a) a compound of formula (I), or a salt thereof;
wherein:
A, B, C, D, W, X, Y and Z are each independently selected from H and OH; and
(b) maltodextrin.

### Claim 2 (depends on 1)

The composition of claim 1, comprising:
(a) about 25% (w/w) to about 50% (w/w) of a compound of formula (I); and
(b) about 50% (w/w) to about 75% (w/w) maltodextrin.

### Claim 3 (depends on 1)

The composition of claim 1, comprising:
(a) 1 part by weight of a compound of formula (I); and
(b) about 1 part to about 3 parts by weight maltodextrin.

### Claim 4 (depends on 1)

The composition of claim 1, comprising:
(a) about 100 mg to about 2000 mg compound of formula (I), for example, urolithin A; and
(b) about 100 mg to about 6000 mg maltodextrin, for example, agglomerated maltodextrin.
wherein the weight ratio of a compound of formula (I) to maltodextrin is either:
(i) about 1 to 1 to about 1 to 3;
(ii) about 1 to 1.5 to about 1 to 2.5; or
(iii) about 1 to 2.5 to about 1 to 3.5.

### Claim 5 (depends on 1)

The composition of claim 1, comprising:
(a) about 100 mg to about 2000 mg compound of formula (I), for example, urolithin A; and
(b) about 150 mg to about 5000 mg maltodextrin, for example, agglomerated maltodextrin,
wherein the weight ratio of a compound of formula (I) to maltodextrin is about 1 to 1.5 to about 1 to 2.5

### Claim 6 (depends on 1)

The composition of claim 1, comprising:
(a) about 500 mg to about 1500 mg compound of formula (I), for example, urolithin A; and
(b) about 750 mg to about 3750 mg maltodextrin, for example, agglomerated maltodextrin,
wherein the weight ratio of a compound of formula (I) to maltodextrin is about 1 to 1.5 to about 1 to 2.5

### Claim 7 (depends on 1)

An aqueous formulation, comprising:
(a) a compound of formula (I), or a salt thereof, as defined in claim 1;
wherein:
A, B, C, D, W, X, Y and Z are each independently selected from H and OH; and
(b) maltodextrin.

### Claim 8 (depends on 7)

The aqueous formulation of claim 7, comprising
(a) 1 part by weight of a compound of formula (I), or a salt thereof; and
(b) about 1 part to about 3 parts by weight maltodextrin.

### Claim 9 (depends on 7)

The aqueous formulation of claim 7, comprising:
(a) about 100 mg to about 2000 mg of a compound of formula (I), or a salt thereof; and
(b) about 100 mg to about 6000 mg maltodextrin,
wherein the weight ratio of a compound of Formula (I), or a salt thereof, to maltodextrin is either:
(a) about 1 to 1 to about 1 to 3;
(b) about 1 to 1.5 to about 1 to 2.5; or
(c) about 1 to 2.5 to about 1 to 3.5.

### Claim 10 (depends on 7)

The aqueous formulation of claim 7, comprising:
(a) about 100 mg/litre to about 8000 mg/litre compound of formula (I), or a salt thereof; and
(b) about 100 mg/litre to about 24 g/litre maltodextrin.

### Claim 11 (depends on 7)

The aqueous formulation of claim 7, comprising either:
(i)
(a) about 0.4 millimolar to about 8.8 millimolar compound of formula (I), or a salt thereof; and
(b) about 0.06 millimolar to about 3.66 millimolar maltodextrin;
or (ii)
(a) about 0.8 millimolar to about 17.6 millimolar compound of formula (I), or a salt thereof; and
(b) about 0.12 millimolar to about 7.31 millimolar maltodextrin;
or (iii)
(a) about 0.4 millimolar to about 8.8 millimolar compound of formula (I), or a salt thereof; and
(b) about 0.24 millimolar to about 7.32 millimolar maltodextrin.

### Claim 12

(canceled)

### Claim 13 (depends on 7)

The aqueous formulation of claim 7, comprising either:
(i)
(a) about 0.4 millimolar to about 8.8 millimolar compound of formula (I), or a salt thereof; and
(b) about 14.7 millimolar to about 128 millimolar maltodextrin;
or (ii)
(a) about 0.8 millimolar to about 17.6 millimolar compound of formula (I), or a salt thereof; and
(b) about 29.4 millimolar to about 256 millimolar maltodextrin;
or (iii)
(a) about 1.6 millimolar to about 35.2 millimolar compound of formula (I), or a salt thereof; and
(b) about 58.8 millimolar to about 512 millimolar maltodextrin.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the compound of formula (I) is selected from urolithin A, urolithin B, urolithin C and/or urolithin D.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the maltodextrin has a DE (dextrose equivalent) of about 5 to about 15.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the maltodextrin is agglomerated maltodextrin.

### Claim 17 (depends on 1)

A method of:
a) increasing or maintaining mitochondrial function;
b) treating, preventing, or managing a mitochondria-related condition associated with altered mitochondrial function or reduced mitochondrial density; and/or
c) treating, preventing, or managing a mitochondria-related disease,
comprising administering to a subject an effective amount of a composition of claim 1.

### Claim 18 (depends on 1)

A method of enhancing muscle performance; improving, maintaining or reducing the loss of muscle function; increasing muscle strength; increasing or maintaining muscle mass; increasing or maintaining muscle recovery; inhibiting or retarding physical fatigue; enhancing working capacity and endurance; or reducing muscle fatigue, comprising administering to a subject an effective amount of a composition of claim 1.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A method of enhancing
a) physical performance, wherein enhancing physical performance comprises at least one effect selected from the group consisting of enhancing athletic performance, enhancing running performance, enhancing muscle performance, enhancing aerobic endurance, enhancing the rating of perceived exertion, lowering post exercise fatigue, enhancing muscle recovery, reducing exercise-induced muscle damage, reducing muscle soreness, and enhancing repair of exercise-induced muscle damage;
b) physical recovery, wherein enhancing physical recovery comprises at least one effect selected from the group consisting of enhancing muscle recovery, enhancing athletic performance, enhancing running performance, enhancing muscle performance, enhancing aerobic endurance, enhancing the rating of perceived exertion, lowering post exercise fatigue, enhancing muscle recovery, reducing exercise-induced muscle damage, reducing muscle soreness, and enhancing repair of exercise-induced muscle damage; and/or
c) physical endurance, wherein enhancing physical endurance comprises at least one effect selected from the group consisting of enhancing muscle recovery, enhancing athletic performance, enhancing running performance, enhancing muscle performance, enhancing aerobic endurance, enhancing the rating of perceived exertion, lowering post exercise fatigue, enhancing muscle recovery, reducing exercise-induced muscle damage, reducing muscle soreness, and enhancing repair of exercise-induced muscle damage,
comprising administering to a subject an effective amount of a composition of claim 1.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A method of maintaining or enhancing skin health; reducing the impact of chronological aging on biological aging; maintaining or enhancing hair health; maintaining or enhancing immune health; maintaining or enhancing brain health; maintaining or enhancing recovery after treatment; increasing healthspan; slowing aging; or increasing longevity; comprising administering to a subject an effective amount of a composition of claim 1.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The composition of claim 1, wherein the compound of formula (I) is urolithin A.
